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Abstract  The incidence of malignant melanoma is rising 
faster than that of any other cancer in the United States. An 
[131I]-labeled benzamide - [131I]MIP-1145 - selectively 
targets melanin, reduces melanoma tumor burden and 
increases survival in preclinical models. Our purpose was to 
determine the potential of radiosensitizers to enhance the 
anti-tumor efficacy of [131I]MIP-1145. Melanotic (A2058) 
and amelanotic (A375 and SK-N-BE(2c)) cells were treated 
with [131I]MIP-1145 as a single agent or in combination with 
drugs with radiosenitizing potential. Cellular uptake of 
[131I]MIP-1145 and toxicity were assessed in monolayer 
culture. The interaction between radiosensitizers and 
[131I]MIP-1145 was evaluated by combination index analysis 
in monolayer cultures and by delayed growth of multicellular 
tumor spheroids. [131I]MIP-1145 was taken up by and was 
toxic to melanotic cells but not amelanotic cells. 
Combination treatments comprising [131I]MIP-1145 with the 
topoisomerase inhibitor topotecan or the PARP-1 inhibitor 
AG014699 resulted in synergistic clonogenic cell kill and 
enhanced delay of the growth of spheroids derived from 
melanotic melanoma cells. The proteasome inhibitor 
bortezomib had no synergistic cytotoxic effect with 
[131I]MIP-1145 and failed to enhance the delay of spheroid 
growth. Following combination treatment of amelanotic 
cells, neither synergistic clonogenic cell kill nor enhanced 
growth delay of spheroids was observed. 
Keywords  Targeted Radiotherapy, Melanoma, 
Radiosensitizer 
 
1. Introduction 
According to the National Cancer Institute, the incidence 
of malignant melanoma has doubled in the last 30 years and 
continues to rise in the United States and UK. 
Chemotherapeutic agents have limited activity in the 
treatment of metastatic melanoma and patients continue to 
have a poor prognosis. Response rates for metastatic 
melanoma with currently available treatments are poor and 
10-year survival is less than 10% [1]. Thus, the advent of 
new, targeted therapies is expected to improve the poor 
results of current therapeutic regimens. 
Targeted radiotherapy seeks to overcome the obstacles 
imposed by metastatic dissemination and the intolerance of 
normal tissue to ionizing radiation. Radiolabeled benzamide 
derivatives bind melanin and exhibit high uptake and 
retention in melanoma cells and in mice bearing melanoma 
tumors [2]. Alkylating benzamides have been shown to 
promote tumor growth delay in preclinical models [3] and 
high tumor uptake of radiolabelled benzamides has been 
observed in vivo [4]. Following the evaluation of a library of 
benzamide compounds, [131I]MIP-1145 
(N-(2-diethylaminoethyl)-4-(4-fluoro-benzamido)-5-iodo-2-
methoxy-benzamide) was selected for entry into clinical 
trials based on its significant melanin-specific tumor uptake 
and retention in vitro and in vivo, anti-tumor activity and 
radiochemical stability and solubility profile [5]. Our aim 
was to establish the most effective use of [131I]MIP-1145 
treatment of melanoma by combination with radiosensitizing 
agents. 
Several classes of drug have been proposed to enhance the 
anti-tumor potency of radiotherapy, including inhibitors of 
poly(ADP-ribose) polymerase-1 (PARP-1), topoisomerase 
and the proteasome. These agents were expected to increase 
radiation-induced DNA damage more effectively in rapidly 
proliferating cancer cells than normal melanocytes. The 
proteasome regulates the degradation of tumor suppressors, 
transcription factors and proteins involved in cell cycle 
control and high levels of proteasome activity have been 
observed in cancer cells [6]. Bortezomib is the first 
proteasome inhibitor approved for the treatment of multiple 
myeloma and has been reported to suppress the growth of 
solid tumors including melanoma [7]. Furthermore, 
bortezomib has been reported to radiosensitize tumors both 
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in experimental models [8] and in patients [9,10]. 
PARP-1 is a DNA repair enzyme which is over-expressed 
in some cancer cells [11]. PARP-1 inhibitors improve the 
efficiency and selectivity of DNA-damaging agents [12], 
indicating their potential as components of combination 
therapy. Ionizing radiation elicited greater damage to DNA 
in PARP-1-deficient mice and cell lines, and replicating 
tumor cells were sensitized to ionizing radiation by PARP-1 
inhibitors [13]. Radiosensitization by PARP-1 inhibitors has 
been demonstrated in human and rodent cell lines [14] and 
in experimental tumors [12]. The PARP-1 inhibitor 
AG014699, a pro-drug of AG014447, has been shown to 
improve the efficacy of the DNA alkylating agent 
temozolomide in preclinical models of medulloblastoma [15] 
and neuroblastoma [16]. Furthermore, the radiosensitizing 
properties of AG14447 have also been demonstrated in vitro 
[17], suggesting similar potential for AG014699. AG014699 
has been shown to be effective in clinical trials and to 
induce minimal toxicity in patients [18,19]. 
DNA unwinding during replication is regulated by 
topoisomerase. Drugs that target topoisomerase stabilize 
topoisomerase-DNA cleavable complexes, leading to 
irreversible DNA double-strand breaks and cell death. 
Combination therapy with topoisomerase poisons and 
targeted radiotherapy has great potential to improve 
treatment efficacy and decrease normal tissue toxicity [20]. 
In particular, the camptothecin analogue topotecan 
sensitizes tumors to radiation in vitro and in vivo [21-25]. 
Topotecan has also been shown to exhibit a tumor-selective 
radiation-sensitizing effect in clinical trials [26]. 
In this study we show that the topoisomerase poison 
topotecan or the PARP-1 inhibitor AG014699 synergized 
with [131I]MIP-1145 in the treatment of melanotic cells 
cultured as monolayers. Furthermore, these agents 
significantly enhanced the [131I]MIP-1145-induced delayed 
growth of melanotic multicellular tumor spheroids. In 
contrast, the proteasome inhibitor bortezomib failed to 
enhance the efficacy in vitro of treatment with 
[131I]MIP-1145. 
2. Materials and Methods 
2.1. Reagents 
Topotecan was purchased from LKT Laboratories Inc 
(Minnesota, USA), AG014699 and bortezomib were 
purchased from Stratech Scientific Limited (Suffolk, UK). 
Stock solutions of agents were prepared in dimethyl 
sulfoxide (DMSO). The maximum DMSO concentration in 
culture medium was 0.1% (v/v). Radiolabeling of 
[131I]MIP-1145 was carried out as previously described [5]. 
2.2. Tissue Culture 
Cell lines A375, A2058 and SK-N-BE(2c) were obtained 
from ATCC and were used in this study for less than 6 
months after resuscitation. Cells were maintained in DMEM 
supplemented with 10% (v/v) (A375 and A2058 cells) or  
15% (v/v) (SK-N-BE(2c) cells) fetal calf serum (Autogen 
Bioclear, Wiltshire, UK) and 1% (v/v) L-glutamine. All 
media were obtained from Gibco (Paisley, UK). 
2.3. Cellular Uptake of [131I]MIP-1145 
Cells were seeded at 105 per well in Costar 6-well culture 
plates and incubated for 2 to 3 days. Confluent cultures were 
incubated with 3.7 kBq [131I]MIP-1145 for various times up 
to 8 hours. At the indicated time, the medium was removed 
and cells were washed twice with PBS to remove the 
compound bound to the cell surface. Radioactivity was 
extracted by treatment with 10% (w/v) trichloroacetic acid 
for 1 h at 4°C. The activity in the extract was measured by 
beta-counting using a Wallac 1450 Trilux Microbeta liquid 
scintillation counter. 
2.4. Clonogenic Survival Assay 
Cells were seeded in 25 cm2 flasks at 2.5 x 105 cells/flask. 
When cultures were in exponential growth phase, medium 
was removed and replaced with fresh medium containing 
[131I]MIP-1145, drugs or combinations of these agents. 
Three different combination treatment schedules were 
assessed: (i) [131I]MIP-1145 and drug administered 
simultaneously, (ii) [131I]MIP-1145 given 24 h before drug, 
(iii) [131I]MIP-1145 administered 24 h after drug. Cells were 
then incubated for 24 h at 37ºC in 5% CO2. After treatment, 
cells were seeded for clonogenic survival assay as previously 
described [24,25]. Cells were incubated at 37°C in 5% CO2 
for 10 to14 days. Colonies were fixed in methanol, stained 
with crystal violet solution (Sigma-Aldrich, UK) and 
counted. 
2.5. Combination Treatments 
The cytotoxic interaction between [131I]MIP-1145 and 
drugs in vitro was assessed according to the method of Chou 
and Talalay [27], which is based on the median-effect 
principle. Briefly, clonogenic assay was carried out using a 
fixed dose ratio of drug to [131I]MIP-1145, based on the 
concentrations required to kill 50% of clonogens (IC50) of 
each single agent, so that the proportional contribution of 
each agent in the mixtures would be the same at all treatment 
intensities. The effectiveness of combinations was quantified 
by calculating a combination index (CI) at various levels of 
cytotoxicity. CI < 1, CI = 1 and CI >1 indicate synergism, 
additivity and antagonism, respectively. 
2.6. Multicellular Spheroids 
SK-N-BE(2c) neuroblastoma cells were used as an 
amelanotic model because A375 cells did not form spheroids. 
Multicellular tumor spheroids (MTS) of A2058 or 
SK-N-BE(2c) cells were obtained using the liquid overlay 
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technique [28]. MTS were initiated by inoculating 3 × 106 
cells into a 25 cm2 plastic flask coated with 1% (w/v) agar. 
After 3 to 4 days, aliquots of spheroids were transferred to 
sterile plastic 25 ml tubes and the spheroids were centrifuged 
at 12 x g for 3 min and re-suspended in 2 ml fresh culture 
medium containing drug. After treatment, the spheroids were 
washed twice by suspension in culture medium, followed by 
centrifugation at 12 x g. Spheroids of approximately 100 µm 
in diameter were transferred individually into agar-coated 
wells of 24-well plates. Individual spheroid growth was 
monitored twice per week for at least three weeks using an 
inverted phase-contrast microscope connected to an image 
acquisition system. Two perpendicular diameters, dmax and 
dmin, were measured using image analysis software (ImageJ) 
and the volume, V (µm3), was calculated using the formula: 
V = π × dmax × dmin² / 6,000,000 [28]. The area under the V/V0 
versus time curve (AUC) was calculated for individual 
spheroids using trapezoidal approximation. 
 
Figure 1.  Uptake of [131I]MIP-1145 by A375, SK-N-BE(2c) or A2058 
cells. Cells were incubated with 3.7 kBq/ml of [131I]MIP-1145 for various 
lengths of time, then cell-associated activity was determined by 
beta-counting. Data are means ± SEM; n=3. ** P < 0.01 compared to 
amelanotic cell lines, † P<0.05 and †† P<0.01 compared to 120 min. 
2.7. Statistical Analysis 
Data are presented as means ± standard error of the mean 
(SEM), unless otherwise stated, with the number of 
independent repetitions provided in the legend to each figure. 
The uptake of [131I]MIP-1145 by melanoma cell lines was 
compared using Student’s t test. A P value < 0.05 was 
considered to be statistically significant and < 0.01 highly 
significant. To test for differences in spheroid growth 
between experimental therapy groups the Kruskal-Wallis 
test was used with post hoc testing by the Mann-Whitney U 
test with Bonferroni correction. Analysis was carried out 
using SPSS software. 
3. Results 
3.1. Binding of [131I]MIP-1145 to Melanotic and 
Amelanotic Cells 
Binding of [131I]MIP-1145 to A375, SK-N-BE(2c) or 
A2058 cells is shown in Figure 1. Binding to melanotic cells 
(A2058) was significantly greater than to amelanotic cells 
(A375 or SK-N-BE(2c)) at all incubation times examined (P 
< 0.01). [131I]MIP-1145 remained bound to melanotic cells 
for at least 8 hours after treatment with the 
radiopharmaceutical (P < 0.01), whereas cell-associated 
radioactivity decreased in amelanotic cells 8 hours after 
treatment compared with earlier time points (P < 0.05). 
3.2. Selective Toxicity of [131I]MIP-1145 to Melanotic 
Cells 
According to clonogenic assay, [131I]MIP-1145 was toxic 
to A2058 cells (melanotic), but not to A375 cells (amelanotic) 
(Figure 2). Furthermore, the growth of spheroids consisting 
of A2058 cells was delayed in a concentration-dependent 
manner by incubation with [131I]MIP-1145 at radioactivity 
concentrations of 0.1 to 10 MBq/ml (Figure 3A). In contrast, 
spheroids consisting of SK-N-BE(2c) cells were unaffected 
by treatment with [131I]MIP-1145 (Figure 3B). 
 
Figure 2.  Toxicity of [131I]MIP-1145. A2058 (melanotic) and A375 
(amelanotic) cells were exposed to [131I]MIP-1145 for 2 hours, before 
cytotoxicity was assessed using clonogenic assay. Data are means ± SEM, 
n=3..
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Figure 3.  The effect on the growth of multi-cellular spheroids of treatment with [131I]MIP-1145. Spheroids consisting of (A) A2058 cells or (B) 
SK-N-BE(2c) cells were exposed to [131I]MIP-1145 for 2 hours, and spheroid size was measured every 3 to 4 days. Data are expressed as mean spheroid 
volume at every time-point divided by original volume (V/V0) ± SEM of 24 spheroids per treatment. 
Table 1.  The effect of administration schedule of the combination of drug 
and [131I]MIP-1145 on the kill of clonogens derived from A2058 cells. 
Combination index values are means of 3 experiments for each alternative 
schedules of administration. CI values < 1 indicate synergy and values > 1 
indicate partial antagonism. Administration schedules were: drug given 24 h 
before [131I]MIP-1145 (pre), simultaneous treatment with drug and 
[131I]MIP-1145 (sim.), drug given 24 h after [131I]MIP-1145 (post). 
Drug Schedule 25% kill 50% kill 75% kill 
Topotecan 
Pre 0.31 0.31 0.33 
Sim. 0.54 0.49 0.49 
Post 0.94 0.88 0.89 
AG014699 
Pre 0.84 0.72 0.62 
Sim. 0.66 0.57 0.49 
Post 1.64 1.36 1.13 
Bortezomib 
Pre 2.09 2.57 3.14 
Sim. 0.83 1.14 1.57 
Post 4.20 6.30 9.50 
3.3. Topotecan and AG014699 Synergized with 
[131I]MIP-1145 in the Treatment of Melanotic Cells 
Combination index analysis was performed to determine 
synergistic interaction between [131I]MIP-1145 and 
radiosensitizers. Agents were administered at fixed dose 
ratios, based on the IC50 values of single agents. The 
following IC50 values were observed following the 
treatment of A2058 cells with topotecan, AG014699 or 
bortezomib: 0.90 M, 7.88 M or 15.74 nM, respectively. In 
the case of A375 cells, the corresponding values were 2.39 M, 
7.96 M or 9.83 nM respectively Three different scheduling 
regimes were compared; (i) drug administered 24 hours 
before [131I]MIP-1145, (ii) drug and [131I]MIP-1145 
administered simultaneously and (iii) [131I]MIP-1145 
administered 24 hours after drug. In Table 1 are shown 
representative CI values calculated at a range of toxicity 
levels (25, 50 and 75% cell kill) for every administration 
schedule. Topotecan, given in combination with 
[131I]MIP-1145, was synergistic (CI < 1) regardless of 
dosing schedule. However, the administration of topotecan 
24 hours before [131I]MIP-1145 or simultaneous 
administration of the two agents were more effective 
schedules than the administration of topotecan 24 hours after 
[131I]MIP-1145. Likewise, AG014699 enhanced the 
toxicity of [131I]MIP-1145 when it was administered 24 
hours before [131I]MIP-1145 or when both agents were 
administered simultaneously. In contrast, the administration 
of AG014699 24 hours after [131I]MIP-1145 had an 
antagonistic effect (CI > 1). Regardless of the sequence of 
administration of agents, combination treatments comprising 
bortezomib and [131I]MIP-1145 resulted in no synergistic 
interaction 
Table 2. The effect of administration schedule of the combination of drug 
and [131I]MIP-1145 on the kill of clonogens derived from A375 cells. 
Drug Schedule 25% kill 50% kill 75% kill 
Topotecan 
Pre 1.16 1.59 2.20 
Sim. 0.95 1.15 1.41 
Post 1.02 1.28 1.60 
AG014699 
Pre 2.62 2.87 3.14 
Sim. 2.14 2.07 2.01 
Post 2.31 2.30 2.29 
Bortezomib 
Pre 2.93 2.62 2.35 
Sim. 2.83 2.18 1.68 
Post 3.48 2.55 1.88 
3.4. [131I]MIP-1145 did not Synergize with 
Radiosensitizers in the Treatment of Amelanotic 
Cells 
In contrast to the increased efficiency of clonogenic cell 
kill resulting from the treatment of melanotic A2058 cells 
with topotecan or AG014699 in combination with 
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[131I]MIP-1145, no synergistic interaction was observed 
following the treatment of amelanotic A375 cells with 
topotecan or AG014699 in combination with [131I]MIP-1145, 
regardless of the sequence of delivery of the agents (Table 2). 
Similarly, in the treatment of A375 cells with combinations 
of bortezomib and [131I]MIP-1145, synergy was not evident 
(CI > 1). 
3.5. Topotecan or AG014699 Enhanced the Delay of the 
Growth of Melanotic Spheroids Induced by 
[131I]MIP-1145 
Multicellular spheroids were treated simultaneously with 
radiosensitizer and [131I]MIP-1145 as this administration 
schedule was observed to be the most effective means of 
sterilising clonogens derived from cellular monolayers. 
[131I]MIP-1145 at 3.7 MBq/ml was used in combination 
treatments because this radioactivity concentration of the 
single agent induced 53% growth delay (according to AUC 
determinations), rather than sterilization of A2058 spheroids 
(Figure 3). The selected concentrations of drugs employed in 
combination treatments were based upon those dosages, as 
single agents, that resulted in approximately 50% inhibition 
of growth of A2058 spheroids, according to AUC 
determinations. Therefore, topotecan was used at 1M, 
AG014699 at 10 M and bortezomib at 5 nM. The effects of 
radiosensitizers and [131I]MIP-1145, alone and in 
combination, on the growth of spheroids derived from 
A2058 or SK-N-BE(2c) cells are shown in Figures 4 and 5, 
respectively. Indices of growth delay induced by 
experimental therapy were the time taken to increase 
spheroid volume 10-fold (10) and the area under the 
volume-time curve (AUC). These values are presented in 
Tables 3 and 4. 
In melanotic spheroids, 3.7 MBq/ml [131I]MIP-1145 
caused a delay in the growth of spheroids (Figure 4), 
exemplified by a decrease in AUC from 1695 (untreated 
control) to 569 ([131I]MIP-1145 alone). Topotecan, 
AG014699 and bortezomib also caused delays as single 
agents at the concentrations used, with AUC values of 986, 
653 and 861, respectively. Combination of [131I]MIP-1145 
with either topotecan or AG014699 resulted in sterilization 
of spheroids; this sterilization result manifest as a failure to 
increase in size throughout the duration of the experiment. 
Although bortezomib enhanced the growth delay effect of 
[131I]MIP-1145 (AUC of combination was 341), it was not as 
effective as topotecan or AG014699. 
As shown by the concentration response in amelanotic 
spheroids (Figure 3B), [131I]MIP-1145 does not have any 
effect on spheroid growth. In amelanotic spheroids (Figure 
5), treatment with drugs alone significantly delayed spheroid 
growth as measured by τ10 and AUC (Table 4). However, 
the addition of [131I]MIP-1145 did not significantly enhance 
this delay in combination with any of the drugs used. 
Table 3.  Comparison of the effect of single agent treatment with 
combination treatment on the growth of A2058 spheroids. Data are means ± 
SEM of 24 spheroids per treatment. Kruskal-Wallis and Mann-Whitney tests 
were performed using SPSS software. * pertains to drug compared with 
[131I]MIP-1145 plus drug. † pertains to [131I]MIP-1145 compared with 
[131I]MIP-1145 plus drug; */† p<0.05, **/†† p<0.01. 
 τ10 AUC 
Control 7.8 ± 1.7 1695 ± 232 
[131I]MIP-1145 9.9 ± 2.1 569 ± 38 
Topotecan 9.0 ± 2.1 986 ± 119 
[131I]MIP-1145 + Topotecan N/A **†† 50 ± 11 **†† 
AG014699 9.9 ± 2.2 653 ± 136 
[131I]MIP-1145 + AG014699 N/A **†† 52 ± 14 **†† 
Bortezomib 8.7 ± 1.9 861 ± 149 
[131I]MIP-1145 + Bortezomib 14.1 ± 1.5 *† 341 ± 91 *† 
Table 4.  Comparison of the effect of single agent treatment with 
combination treatment on the growth of SK-N-BE(2c) spheroids. Data are 
means ± SEM of 24 spheroids per treatment. Kruskal-Wallis and 
Mann-Whitney tests were performed using SPSS software. †† p<0.01 
compared to [131I]MIP-1145 alone. 
 τ10 AUC 
Control 5.4 ± 1.1 1027 ± 143 
[131I]MIP-1145 4.8 ± 1.1 1319 ± 105 
Topotecan 7.9 ± 1.0 674 ± 91 
[131I]MIP-1145 + Topotecan 9.1 ± 1.3 †† 574 ± 80 †† 
AG014699 8.1 ± 1.1 542 ± 52 
[131I]MIP-1145 + AG014699 7.1 ± 1.2 †† 610 ± 93 †† 
Bortezomib 7.1 ± 1.4 725 ± 67 
[131I]MIP-1145 + Bortezomib 7.5 ± 1.0 †† 824 ± 101 †† 
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Figure 4.  The effect on A2058 spheroid growth of single agent or combination treatment. Multi-cellular spheroids derived from A2058 cells were treated 
with 3.7 MBq/ml [131I]MIP-1145 and (A) 1 µM topotecan, (B) 10 µM AG014699, (C) 5 nM bortezomib as single agents or in combination. Data are 
expressed as mean spheroid volume at each time-point divided by original volume (V/V0) ± SEM of 24 spheroids per treatment. 
 
Figure 5.  The effect on SK-N-BE(2c) spheroid growth of single agent or combination treatment. Multi-cellular spheroids derived from SK-N-BE(2c) cells 
were treated with 3.7 MBq/ml [131I]MIP-1145 and (A) 1 µM topotecan, (B) 10 µM AG014699, (C) 5 nM bortezomib as single agents or in combination. Data 
are expressed as mean spheroid volume at each time-point divided by original volume (V/V0) ± SEM of 24 spheroids per treatment. 
4. Discussion 
The combination of radiotherapy and chemotherapy is an 
appealing approach that has led to improved treatment 
results in many patients with advanced solid tumors [29]. 
However, response rates for metastatic melanoma using 
currently available treatments are poor [1]. In this study 
[131I]MIP-1145, a benzamide compound that has been shown 
to specifically target melanin [5], was used in combination 
with potential radiosensitizers in an attempt to maximize 
damage in malignant deposits. 
Our findings indicate that [131I]MIP-1145 was taken up 
by the melanin-expressing cell line, and this is in line with 
the previous report of melanin-specific uptake of this agent 
in vitro [5]. The combination index method, based on the 
median-effect principle of Chou and Talalay [27], was used 
to analyse synergistic cytotoxicity. Three different 
administration regimes were evaluated because previous 
studies of combination treatment comprising 
radiosensitizers and targeted radionuclides showed that 
scheduling was an important determinant of synergy [24,25]. 
Experimental treatment of melanotic cells using topotecan 
in combination with [131I]MIP-1145 was synergistic 
regardless of schedule of administration. This observation is 
in agreement with reports of topotecan’s capacity to 
radiosensitize a variety of solid tumors [21-23]. The 
enhancement of efficacy of [131I]MIP-1145 by combining 
with topotecan is likely the result of inhibition of DNA 
damage repair, as was previously demonstrated in similar 
studies assessing the combination treatment of 
neuroblastoma cells with [131I]MIBG and topotecan [24]. 
Encouraging results have been obtained using topotecan 
combined with radiotherapy for patients with lung cancer 
[26,30]. Neither single agent treatment with [131I]MIP-1145 
nor combination treatment with [131I]MIP-1145 and 
topotecan was effective in the sterilization of amelanotic 
cells, confirming the melanin specificity of the 
radiopharmaceutical. 
DNA repair is a potential target pathway for tumors and 
inhibitors of repair have shown to be effective 
radiosensitizers [14]. In this study, the PARP-1 inhibitor 
AG014699 showed the greatest enhancing effect when 
administered either simultaneously or before the addition of 
[131I]MIP-1145 in melanotic cells, suggesting that 
scheduling is important with this drug. PARP-1 binds to 
both single- and double-stranded DNA breaks, partly via the 
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base excision pathway, which plays an important role in 
repairing single-strand breaks induced by ionizing radiation 
[31]. We predict that PARP-1 inhibition promotes increased 
formation of DNA single strand breaks which are 
subsequently converted to potentially lethal double strand 
breaks during cell replication. This is possible with 
simultaneous administration or administration of inhibitor 
24 hours prior to [131I]MIP-1145, whereas administration of 
AG014699 24 hours after [131I]MIP-1145 is likely to allow 
sufficient DNA repair to occur. Initial clinical trials have 
indicated that AG014699 is safe and tolerable and 
combination treatments with temolozolomide have shown 
encouraging results in melanoma patients [18,19]. 
AG014699 has also been used as a radiosensitizer in phase I 
and II clinical trials in head and neck cancers and CNS 
neoplasm [32,33], indicating its potential in other solid 
tumors. Cancers bearing mutations in either the BRCA1 or 
BRCA2 genes were extremely susceptible to PARP 
inhibitors [34] and AG014699 is currently being assessed in 
BRCA-deficient ovarian and breast cancer patients [35]. 
BRCA mutations have also been associated with some 
melanomas [36], suggesting that PARP inhibitors would be 
a particularly useful addition to the treatment of this cancer. 
Although bortezomib has anti-tumor activity as a single 
agent in multiple myeloma [37], its use for solid tumors is 
controversial [38]. It was toxic to melanoma cells in vitro as 
a single agent [39,40], but displayed minimal activity in 
patients [41] and was associated with dose-limiting toxicities 
[42]. In combination studies, bortezomib did not enhance the 
effects of heat shock protein inhibitors in a melanoma cell 
line [43] or paclitaxel in melanoma patients [41]. The 
sequence of administration has been shown to be important 
when combining bortezomib with chemotherapeutic agents, 
although conflicting views on the optimal dosing schedule 
have been reported [44,45]. The radiosensitizing effect of 
bortezomib has previously been reported [8,46], but was lost 
when radiotherapy dose was fractionated [47]. In this study, 
the administration of bortezomib simultaneously with 
[131I]MIP-1145 in melanotic cells showed no synergistic 
effect, and less synergy than either topotecan or AG014699 
when administered before or after [131I]MIP-1145. 
One of the major pathways of bortezomib action is the 
generation of reactive oxygen species (ROS) [48]. Due to the 
production of high levels of oxygen-containing radicals 
during melanin biosynthesis, melanoma cells contain high 
levels of ROS [49]. Drug or radiation treatment likely results 
in elevation of ROS levels above a threshold level, causing 
cell death. It is therefore possible that the radiation- or 
bortezomib-induced ROS generation is maximal after single 
agent treatment of the melanoma cells used here, resulting in 
the lack of additive or synergistic effect of the combination 
observed in this study. Neither topotecan nor AG014699 are 
thought to act through ROS generation. 
We have previously evaluated the efficacy of targeted 
radionuclide treatment in vitro in a three dimensional tumor 
spheroid model [50,51]. These models are useful for 
determining the dependence of novel targeted radionuclide 
therapy strategies on cycling and oxygenation status (factors 
which influence the toxicity of radionuclides) because they 
are composed of cells in the range of proliferative states. The 
major target of radionuclide therapy is disseminated 
malignant deposits of millimetre dimensions. Melanotic and 
amelanotic spheroids were exposed to a range of doses of 
[131I]MIP-1145 to determine their responsiveness to the 
radiopharmaceutical. As expected, melanotic spheroids 
responded in a concentration-dependent manner, whereas 
amelanotic spheroids did not show any growth delay in 
response to treatment. In agreement with the monolayer 
experiments described above, both topotecan and AG014699 
were shown to enhance growth delay in melanotic spheroids, 
with significant enhancement of [131I]MIP-1145-induced 
delay in growth when administered in combination. 
Combined treatment of [131I]MIP-1145 with bortezomib in 
melanotic spheroids did not result in a significantly enhanced 
growth delay. As predicted, [131I]MIP-1145 did not have any 
effect on amelanotic spheroids and therefore did not cause a 
growth delay when combined with any of the drugs. 
The search for a radiopharmaceutical with a selective 
affinity for melanoma tissue is of utmost importance both 
for the early detection of local recurrences to allow efficient 
surgical excision and for treatment of in-transit or 
developed metastases. Most melanomas are pigmented by 
the presence of melanin, an intracellular melanocyte 
pigment. Some melanomas are called amelanotic because 
they are not black or darkly pigmented. However, even 
amelanotic melanomas contain some melanin [52,53] which 
makes this pigment a convenient target for development of 
radionuclide therapy of metastatic melanoma. This makes 
[131I]MIP-1145, which specifically targets melanin, an ideal 
candidate for targeted therapy of melanoma. The feasibility 
of targeting melanin to deliver cytotoxic radiation to human 
melanoma cells in vivo was demonstrated using a fungal 
melanin-binding monoclonal antibody with promising 
therapeutic results [54]. Although targeted therapy was 
previously thought to be suited to micrometastasis, targeted 
alpha therapy has been used in a phase I trial for metastatic 
melanoma [55], giving hope that these therapies can be used 
for solid tumors. Targeted radionuclide therapy concentrates 
the effects on tumor cells, thereby increasing the efficacy 
and decreasing the morbidity of radiotherapy, and there has 
also been a recent report of a radiolabeled peptide therapy 
in trial for metastatic melanoma [56], suggesting promise 
for targeted therapy in this disease. It is now hoped that 
combination with suitable radiosensitizing drugs will 
enhance the effect of these targeted radiotherapies. 
5. Conclusions 
The results described in this study suggest that 
combination of [131I]MIP-1145 with some, but not all, 
chemotherapeutic drugs could be an effective treatment for 
melanoma. The specificity of [131I]MIP-1145 to target only 
melanin-expressing cells means reduced off-target effects, 
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and in combination with radiosensitizers such as topotecan 
or AG014699, suggests a promising therapeutic approach. 
However this will require to be confirmed in other 
melanin-expressing cells and pre-clinical models. 
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